



The Role of Hypofractionated Radiotherapy in Modern Oncology

Guest Editors:

Dr. Mateusz Spątek

Dr. Aleksandra Napieralska

Dr. Bartłomiej Tomasiak

Deadline for manuscript
submissions:
closed (31 May 2023)

Message from the Guest Editors

Dear Colleagues,

Advances in current radiation oncology enabled more precise dose delivery with significant sparing of surrounding healthy tissues. Thus, the fear of late complications associated with a higher dose per fraction was drastically reduced. Moreover, radiobiological research suggested more complex interactions between various fraction doses with modern systemic treatments such as immunotherapy than those calculated using radiobiological models. Various regimens of hypofractionated radiotherapy were and are investigated in various clinical trials that confirmed their safety and efficacy. This Special Issue includes original reports and reviews that highlight biological and clinical aspects of hypofractionation in modern oncology. We also welcome studies regarding ultra-hypofractionation (SBRT, SRS).

The main areas of interest are:

- The biological basis of hypofractionation;
- Novel indications for hypofractionated radiotherapy;
- The combination of hypofractionated regimens with systemic treatment and radiosensitizers.

Dr. Mateusz Spątek

Dr. Aleksandra Napieralska

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI